Automated synthesis of Ga-68/Lu-177-PSMA on the Trasis miniAllinOne

5 Citations (Scopus)

Abstract

Prostate-specific membrane antigen (PSMA)-based radioligands for positron emission tomography (PET)/computed tomography (CT) studies represent the gold standard for detection of recurrent prostate cancer (PCa). [ 68Ga]PSMA-HBED-CC is a PET radiotracer suitable for detection of PCa, and its clinical use has become widespread over the last few years. In this contribution, we detail our GMP-compliant production of [ 68Ga]PSMA-HBED-CC using the Trasis miniAllinOne radiosynthesizer and report synthetic and clinical data for the first 100 productions of 2019. Additionally, we detail our efforts towards a GMP-compliant production of the radiotherapeutic [ 177Lu]PSMA-I&T using the same synthesis module. PSMA-based radioligand therapy (RLT) offers a possible future treatment in cases of metastatic castration-resistant PCa, and GMP-compliant routine production methods are therefore called for. This report highlights how PSMA-based agents for theranostic purposes can be conveniently produced at a single radiochemistry Good Manufacturing Practice (GMP) site, thereby facilitating optimized detection and treatment of PCa.

Original languageEnglish
JournalJournal of Labelled Compounds and Radiopharmaceuticals
Volume63
Issue number8
Pages (from-to)393-403
Number of pages11
ISSN0362-4803
DOIs
Publication statusPublished - 30 Jun 2020

Keywords

  • GMP
  • PET/CT
  • prostate cancer
  • PSMA
  • [ Lu]PSMA-I&T
  • [ Ga]PSMA-HBED-CC

Fingerprint

Dive into the research topics of 'Automated synthesis of Ga-68/Lu-177-PSMA on the Trasis miniAllinOne'. Together they form a unique fingerprint.

Cite this